Anti-HCV antiviral therapies as an alternative for the treatment of Covid-19

Authors

DOI:

https://doi.org/10.33448/rsd-v9i10.9406

Keywords:

Sars-cov-2; Hepatitis c virus; Antiviral; Treatment.

Abstract

The current pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread alarmingly around the world at a significantly faster speed than previous coronaviral outbreaks. Due to the lack of a vaccine at the moment, an early antiviral intervention can prevent the spread of the disease worldwide and improve the clinical results of infected patients. The SARS-CoV-2 virus and the Hepatitis C virus (HCV) have a similar structure, replication, and catalytic mechanisms, therefore, several studies have considered the potential for antiviral activity of anti-HCV drugs such as remdesivir, simeprevir, sofosbuvir, and daclatasvir against SARS-CoV-2. Therefore, the present study aims to evaluate and discuss the antivirals already available against HCV, which have also been shown to be potential inhibitors of SARS-CoV-2 replication. The study was based on a literature review, of a qualitative nature and an exploratory type. Studies with anti-HCV drugs are promising and are already considered to start clinical trials in patients infected with the new coronavirus, having been observed as inhibitors of SARS-CoV-2 viral replication. Thus, the present study brings a pharmaco-clinical review on antivirals remdesivir, simeprevir, sofosbuvir, and daclatasvir, considering the main studies carried out to date in the treatment for Covid-19.

References

Agostini, M. L., Andres, E. L., Sims, A. C., Graham, R. L., et al., (2018). Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio, 9(2). Doi: 10.1128/mbio.00221-18

Alamri, M. A., Tahir ul Qamar, M., Mirza, M. U., Bhadane, R., et al., (2020). Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CLpro. Journal of Biomolecular Structure and Dynamics, 1–13. Doi: 10.1080/07391102.2020.1782768

Asadi-Pooya, A. A., & Simani, L. (2020). Central nervous system manifestations of COVID-19: A systematic review. Journal of the Neurological Sciences, 116832. Doi:10.1016/j.jns.2020.116832

Bryan-Marrugo, O. L., Ramos-Jiménez, J., Barrera-Saldaña, H., Rojas-Martínez, A., Vidaltamayo, R., & Rivas-Estilla, A. M. (2015). History and progress of antiviral drugs: From acyclovir to direct-acting antiviral agents (DAAs) for Hepatitis C. Medicina Universitaria, 17(68), 165–174. Doi: 10.1016/j.rmu.2015.05.003

Brown, A. J., Won, J. J., Graham, R. L., Dinnon, K. H., et al., (2019) Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral research 169, 104541. Doi: 10.1016/j.antiviral.2019.104541

Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., et al., (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, The Lancet. 395 (10223), 507–513. Doi: 10.1016/S0140-6736(20)30211-7

Chen, Y. W., Yiu, C-P. B., & Wong, K-Y. (2020). Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Research, 9:129. Doi: 10.12688/f1000research.22457.2

Chien, M., Anderson, T. K., Jockusch, S., Tao, C., et al., (2020). Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19. Journal of Proteome Research. Doi: 10.1021/acs.jproteome.0c00392

Deng, C. X. (2020). The global battle against SARS-CoV-2 and COVID-19. International journal of biological sciences, 16(10), 1676. Doi: 10.7150/ijbs.45587

De Clercq, E., & Li, G. (2016). Approved Antiviral Drugs over the Past 50 Years. Clinical Microbiology Reviews, 29(3), 695–747. Doi: 10.1128/cmr.00102-15

Dustin, L. B., Bartolini, B., Capobianchi, M. R., & Pistello, M. (2016). Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy. Clin. Microbiol. Infect, 22, 826–832. Doi: 10.1016/j.cmi.2016.08.025

Elfiky, A. A. (2020). Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sciences, 117592. Doi:10.1016/j.lfs.2020.117592

Gandhi, Y., Eley, T., Fura, A., Li, W., et al., (2018). Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics. Clinical Pharmacokinetics, 57(8), 911–928. Doi:10.1007/s40262-017-0624-3

Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., et al., (2020). A SARS-CoV-2 protein

interaction map reveals targets for drug repurposing. Nature. Doi: 10.1038/s41586-020-2286-9

Gordon, C. J., Tchesnokov, E. P., Woolner, E., Perry, J. K., et al., (2020). Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. Journal of Biological Chemistry, 013679. Doi: 10.1074/jbc.ra120.013679

Gordon, C. J., Tchesnokov, E. P., Feng, J. Y., Porter, D. P., & Gotte, M. (2020). The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. Journal of Biological Chemistry, 013056. Doi:10.1074/jbc.ac120.013056

Hui, D. S., I Azhar, E., Madani, T. A., Ntoumi, F., et al., (2020). The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China. International Journal of Infectious Diseases, 91, 264–266. Doi:10.1016/j.ijid.2020.01.009

Hui, D. S. C. & Zumla, A. (2019). Severe acute respiratory syndrome: historical, epidemiological and clinical features. Infect. Dis. Clin. N. Am. 33, 869–889. Doi: 10.1016/j.idc.2019.07.001

Hosseini, F. S., & Amanlou, M. (2020). Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study. Life Sciences, 118205. Doi: 10.1016/j.lfs.2020.118205

Ju, J., Kumar, S., Li, X., Jockusch, S., & Russo, J. J. (2020). Nucleotide Analogues as Inhibitors of Viral Polymerases. bioRxiv, 927-574. Doi: 10.1101/2020.01.30.927574

Keating, G. M. (2016). Daclatasvir: A Review in Chronic Hepatitis C. Drugs, 76(14), 1381–1391. doi:10.1007/s40265-016-0632-x

Keating, G. M. (2014). Sofosbuvir: A Review of its Use in Patients with Chronic Hepatitis C. Drugs, 74(10), 1127–1146. Doi: 10.1007/s40265-014-0247-z

Li, H., Zhou, Y., Zhang, M., Wang, H., et al., (2020) Updated approaches against SARS-CoV-2. Antimicrobial agents and chemotherapy, 64(6). Doi: 10.1128/AAC.00483-20

Liu, J., Cao, R., Xu, M., Wang, X., et al., (2020). Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery, 6(1). Doi:10.1038/s41421-020-0156-0

Lu, H. (2020). Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 14(1):69–71. Doi: 10.5582/bst.2020.01020.

Lu, R., Zhao, X., Li, J., Niu, P., et al., (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for irus origins and receptor binding. Lancet, 395, 565-574. Doi: 10.1016/S0140-6736(20)30251

Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020). Developing Covid-19 vaccines at pandemic speed. New England Journal of Medicine, 382(21), 1969-1973. Doi: 10.1056/NEJMp2005630

Lo, H. S., Hui, K. P., Lai, H. M., Khan, K. S., et al., (2020). Simeprevir suppresses SARS-CoV-2 replication and synergizes with remdesivir. bioRxiv. Doi: 10.1101/2020.05.26.116020

Lotfi, M., Hamblin, M. R., & Rezaei, N. (2020). COVID-19: Transmission, Prevention, and Potential Therapeutic Opportunities. Clinica Chimica Acta. Doi:10.1016/j.cca.2020.05.044

Mesci, P., Macia, A., Saleh, A., Martin-Sancho, L., et al., (2020). Sofosbuvir protects human brain organoids against SARS-CoV-2. bioRxiv. 125-856. Doi: 10.1101/2020.05.30.125856

Pereira, A. S, Shitsuka, D. M, Parreira, F. J., & Shitsuka, R. (2018). Metodologia da pesquisa científica. [e-book]. Santa Maria. Ed. UAB/NTE/UFSM. Accessed on August 19, at https://repositorio.ufsm.br/bitstream/handle/1/15824/Lic_Computacao_Metodologia-Pesquisa-Cientifica.pdf?sequence=1.

Rosenquist, Å., Samuelsson, B., Johansson, P.-O., Cummings, M. D., et al., (2014). Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor. Journal of Medicinal Chemistry, 57(5), 1673–1693. Doi: 10.1021/jm401507s

Sacramento, C. Q., Rodrigues, N. F., Temerozo, J. R., Dias, S., et al., (2020). The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2. bioRxiv. Doi: 10.1101/2020.06.15.153411

Sheahan, T. P., Sims, A. C., Leist, S. R., Schafer, A., et al., (2020). Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature communications 11, 222. Doi: 10.1038/s41467-019-13940-6

Siegel, D., Hui, H. C., Doerffler, E., Clarke, M. O., et al., (2017). Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses. J Med Chem. 60(5):1648–61. Doi: 10.1021/acs.jmedchem.6b01594.

Smith, M. A., Regal, R. E., & Mohammad, R. A. (2015). Daclatasvir. Annals of Pharmacotherapy, 50(1), 39–46. Doi:10.1177/1060028015610342

Tchesnokov, E., Feng, J., Porter, D., & Götte, M. (2019). Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir. Viruses, 11(4), 326. Doi:10.3390/v11040326

Verbinnen, T., Fevery, B., Vijgen, L., Jacobs, T., De Meyer, S., & Lenz, O. (2015). In VitroActivity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants. Antimicrobial Agents and Chemotherapy, 59(12), 7548–7557. Doi:10.1128/aac.01444-15

Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020). Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. Journal of Virology. Doi:10.1128/jvi.00127-20

Wang, Y., Zhang, D., Du, G., Du, R., et al., (2020). Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 395(10236), 1569-78. Doi: 10.1016/S0140-6736(20)31022-9.

Wang, M., Cao, R., Zhang, L., Yang, X., et al., (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research; 30: 269-71. Doi: 10.1038/s41422-020-0282-0

Wu, R., Wang, L., Kuo, H.-C. D., Shannar, A., Peter, R., Chou, P. J., …, & Kong, A.-N. (2020). An Update on Current Therapeutic Drugs Treating COVID-19. Current Pharmacology Reports 6, 56–70. Doi: 10.1007/s40495-020-00216-7

Zumla, A.; Chan, J. F. W.; Azhar, E. I.; Hui, D. S. C, & Yuen, K. Y. (2016). Coronaviruses – drug discovery and therapeutic options. Nat. Rev. | Drug Discovery, 15, 327-347. Doi: 10.1038/nrd.2015.37

Zhou, P.; Yang, X.; Wang, X.; Hu, B., & Zhang, L. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579: 270-273. Doi: 10.1038/s41586-020-2012-7

Zhou, N.; Zhang, D.; Wang, W.; Li, X., & Yang, B. (2020). Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl J. Med. 382;8. Doi: 10.1056/NEJMoa2001017

Downloads

Published

28/10/2020

How to Cite

MEDEIROS, G. R. de; FARIAS , I. C. C.; FARIAS, J. V. C.; MACEDO, P. R. de. Anti-HCV antiviral therapies as an alternative for the treatment of Covid-19. Research, Society and Development, [S. l.], v. 9, n. 10, p. e9489109406, 2020. DOI: 10.33448/rsd-v9i10.9406. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/9406. Acesso em: 14 nov. 2024.

Issue

Section

Review Article